PMID- 16964594
OWN - NLM
STAT- MEDLINE
DCOM- 20070329
LR  - 20070814
IS  - 1527-6465 (Print)
IS  - 1527-6465 (Linking)
VI  - 13
IP  - 1
DP  - 2007 Jan
TI  - Impact of human leukocyte antigen mismatching on outcomes of living donor liver 
      transplantation for primary biliary cirrhosis.
PG  - 80-90
AB  - Patient selection criteria of deceased donor liver transplantation for primary 
      biliary cirrhosis (PBC) are almost completely established. The aim of this study 
      was to establish selection criteria for both patients and donors of living donor 
      liver transplantation (LDLT) for PBC. We used univariate and multivariate 
      analyses to examine patient and donor characteristics of our first 50 cases of 
      LDLT for PBC to elucidate factors that significantly impacted patient survival or 
      disease recurrence after LDLT in the univariate and/or multivariate analyses. 
      Multivariate analysis demonstrated that the presence of persistent ascites before 
      LDLT, a higher number of human leukocyte antigen (HLA)-A, -B, and -DR mismatches 
      between donor and recipient, and donor age >or=50 years were factors 
      significantly associated with early posttransplant death. Independent risk 
      factors for PBC recurrence after LDLT were a lower number of HLA mismatches 
      between donor and recipient, and a lower average trough level of tacrolimus 
      within 1 year after LDLT. Specifically, the lower the number of HLA-A, -B, and 
      -DR mismatches or the average trough level of tacrolimus within 1 year after 
      LDLT, the higher the possibility of developing a recurrence of PBC. In 
      conclusion, the absence of persistent ascites before LDLT, a lower number of 
      HLA-A, -B, and -DR mismatches between donor and recipient, and a younger donor 
      (<50 years) are preferred for gaining acceptable survival outcomes for the 
      transplant. However, a lower number of HLA-A, -B, and -DR mismatches between 
      donor and recipient may be a risk factor for PBC recurrence.
CI  - (c) 2006 AASLD.
FAU - Morioka, Daisuke
AU  - Morioka D
AD  - Organ Transplant Unit, Kyoto University Hospital, Kyoto. dmorioka@hotmail.com
FAU - Egawa, Hiroto
AU  - Egawa H
FAU - Kasahara, Mureo
AU  - Kasahara M
FAU - Jo, Tomoyasu
AU  - Jo T
FAU - Sakamoto, Seisuke
AU  - Sakamoto S
FAU - Ogura, Yasuhiro
AU  - Ogura Y
FAU - Haga, Hironori
AU  - Haga H
FAU - Takada, Yasutsugu
AU  - Takada Y
FAU - Shimada, Hiroshi
AU  - Shimada H
FAU - Tanaka, Koichi
AU  - Tanaka K
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Liver Transpl
JT  - Liver transplantation : official publication of the American Association for the 
      Study of Liver Diseases and the International Liver Transplantation Society
JID - 100909185
RN  - 0 (HLA Antigens)
SB  - IM
CIN - Liver Transpl. 2007 Jan;13(1):8-13. PMID: 17192903
CIN - Liver Transpl. 2007 Jun;13(6):938-9. PMID: 17538993
MH  - Adult
MH  - Aged
MH  - Female
MH  - Graft Survival/immunology
MH  - HLA Antigens/*metabolism
MH  - *Histocompatibility Testing
MH  - Humans
MH  - Liver Cirrhosis, Biliary/genetics/*mortality/*surgery/*therapy
MH  - Liver Transplantation/*methods
MH  - Living Donors
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Recurrence
MH  - Risk Factors
MH  - Time Factors
MH  - Treatment Outcome
EDAT- 2006/09/12 09:00
MHDA- 2007/03/30 09:00
CRDT- 2006/09/12 09:00
PHST- 2006/09/12 09:00 [pubmed]
PHST- 2007/03/30 09:00 [medline]
PHST- 2006/09/12 09:00 [entrez]
AID - 10.1002/lt.20856 [doi]
PST - ppublish
SO  - Liver Transpl. 2007 Jan;13(1):80-90. doi: 10.1002/lt.20856.